Please login to the form below

Not currently logged in
Email:
Password:

leukaemia

This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

The drug has been approved for chronic lymphocytic leukaemia (CLL) since 2016 and picked up a second indication in acute myeloid leukaemia (AML) last year, but analyst Steve Scala at Cowen

Latest news

  • Roche files Venclexta plus Gazyva in CLL Roche files Venclexta plus Gazyva in CLL

    Sandra Horning. "More than 20, 000 people will be diagnosed with untreated chronic lymphocytic leukaemia in the US this year, and many are ineligible for intensive chemotherapy-based options," said Sandra ... the agency to bring this new option to people

  • Xencor’s Novartis-partnered bispecific on hold after patient deaths Xencor’s Novartis-partnered bispecific on hold after patient deaths

    The two death’s included one case of CRS. Xencor has had a clinical hold placed on its phase 1 trial of a bispecific antibody for acute myeloid leukaemia (AML) after ... Amgen’s already-approved Blincyto (blinatumomab) for acute lymphoblastic

  • CMS proposes coverage scheme for CAR-T therapies CMS proposes coverage scheme for CAR-T therapies

    The first CAR-T to be approved by the FDA was Novartis’ Kymriah (tisagenlecleucel) for B-cell precursor acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL), with Gilead ... These one-time treatments have shown remarkable

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    BTK inhibitor Calquence (acalabrutinib) – a rival to Johnson/AbbVie's big-selling Imbruvica (ibrutinib) – could be filed for chronic lymphocytic leukaemia (CLL) before year-end extending its current use in mantle

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    Last year NICE approved its use in children and young adults with Acute Lymphoblastic Leukaemia (ALL), with NHS England heralding its market access clearance as one of the earliest in Europe.

More from news
Approximately 71 fully matching, plus 358 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    An 11-month old baby suffering from CD19-positive acute lymphoblastic leukaemia (ALL) was treated with modified donor T cells that had been engineered to attack leukaemia cells.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours. ... are ineligible for intensive chemotherapy, to go along with its existing indications in chronic lymphocytic leukaemia (CLL).

  • Deal Watch October 2018

    AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim. ... Manufacture and supply of

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    Novartis’ leukaemia treatment Glivec.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater unmet needs, such as gastric cancer, acute myelocytic leukaemia ... antigen receptor T-cell (CAR-T) therapies from

More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics